SK Biopharm, Subscription Competition Rate 323.02 to 1... 31 Trillion Won in Deposit Funds Gathered
[Asia Economy Reporter Hyungsoo Park] NH Investment & Securities, the lead underwriter for SK Biopharm's listing, announced on the 24th that the general public subscription held over two days from the 23rd to the 24th recorded a competition rate of 323.02 to 1. The general subscription deposit was estimated at approximately 30.99 trillion KRW.
SK Biopharm conducted a demand forecast targeting institutional investors from the 17th to the 18th, with 1,076 domestic and international institutions participating, recording a competition rate of 835.66 to 1.
An NH Investment & Securities official stated, "It appears that SK Biopharm's unique core technology and global growth potential during the IPO process led to investor trust."
Hot Picks Today
"You Might Regret Not Buying Now"... Overseas Retail Investors Stirred by News of Record-Breaking Monster Stocks' IPOs
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- Mistaken for the Flu, Left Untreated... Death Toll Surges as WHO Declares Emergency (Comprehensive)
- "Russia Launches Large-Scale Nuclear Drills During Putin's Visit to China"
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
SK Biopharm plans to use the funds raised through the initial public offering (IPO) for growth resources such as innovative new drug research, development, and commercialization.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
